Preliminary Fourth Quarter 2025 Financial Results
Q4 and FY2025 revenues of £0.4m and £1.4m respectively, below guidance; cost cuts of £5.9m announced.
vs expectations: below
- Q4 2025 revenue £0.4m
- Full year 2025 revenue £1.4m
- Full year biopharma and product revenues £0.3m and £1.1m
- Cash at 31 December 2025 £7.3m
- Annualised cost savings £5.9m
- Qualified 2026/27 sales pipeline £12.6m (risk weighted £4.5m)
Select text to share a quote on X · sign in to keep highlights & notes in your CLBX notes
Guildford, UK and Plymouth Meeting, US - 16 January 2026 - CelLBxHealth plc (AIM:CLBX), a leader in circulating tumour cell (CTC) intelligence, with tests and services supporting research, drug development and clinical oncology, announces an update on 2025 unaudited financial results and further cost rationalisation as it looks to drive commercial progress in 2026.
Preliminary 2025 financial results
The Company now expects to report fourth quarter and full year 2025 revenues of approximately £0.4 million and £1.4 million respectively. The full year biopharma and product revenues were £0.3 million and £1.1 million respectively. The Company was expecting to achieve revenues of £1.6million for the year ended 31 December 2025, however a few sales contracts, with an aggregate value of approximately £0.2 million, were deferred into the first quarter of 2026.
Cash at 31 December 2025 was £7.3 million, providing a strong balance sheet from which to execute on the new strategy.
Cost rationalisation
The Company is reducing costs at all levels and consequently has voluntarily delisted its ordinary shares from trading on the OTCQX Market due to low trading volume and the associated administrative requirements. The Company's last day of trading on the OTCQX Market was 31 December 2025. Beginning 2 January 2026, the Company has transitioned to trading on the Pink Limited Market.
The Company is also rationalising its operations at Guildford into one facility. Along with headcount reductions and other restructuring activities, total cost savings are expected to be approximately £5.9 million on an annualised basis.
Outlook for 2026
Further to the fundraising announced in late November 2025, the Company is now pursuing its revised business strategy, focused on the delivery of commercial milestones from its qualified 2026/27 sales pipeline of approximately £12.6 million (risk weighted pipeline of £4.5 million), which underpins its revenue growth targets
2026 Reporting Calendar
- April 2026: Q1 2026 financial results and business update
- June 2026: preliminary FY2025 financial results
- June 30, 2026: Annual general shareholders' meeting
- July 2026: Q2 2026 financial results and business update
- November 2026: Q3 2026 financial results and business update
Financial information and auditor review
The preliminary unaudited financial information for the year ended 31 December 2025 set out above has been prepared from the Company's internal management accounts. The Company has not yet finalised its results for the year ended 31 December 2025. Accordingly, the final audited results may differ from the preliminary unaudited financial information presented above, and such differences may be material.
Peter Collins CEO of CelLBxHealth commented:
'The Company remains on track with the execution of its organisational restructure and delivery of associated cost-saving measures. With management focused on refining the Company's business strategy, securing funding and implementing the restructure during the fourth quarter of 2025, some sales contracts, with an aggregate value of approximately £0.2 million, were deferred into the first quarter of 2026.'
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.